Bruker (NASDAQ:BRKR - Get Free Report) announced its earnings results on Thursday. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01, Zacks reports. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker updated its FY 2025 guidance to 2.670-2.720 EPS.
Bruker Stock Performance
Shares of NASDAQ:BRKR traded down $1.11 during trading on Monday, reaching $50.04. The company had a trading volume of 2,044,498 shares, compared to its average volume of 1,412,424. The stock's fifty day moving average price is $57.56 and its 200 day moving average price is $60.48. Bruker has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The firm has a market capitalization of $7.59 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.
Analyst Ratings Changes
BRKR has been the subject of several recent analyst reports. UBS Group initiated coverage on Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 target price for the company. TD Cowen cut their price target on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research report on Wednesday, November 6th. Bank of America lifted their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. Finally, Citigroup dropped their target price on Bruker from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.50.
Get Our Latest Stock Report on BRKR
About Bruker
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
